FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593623152> ?p ?o ?g. }

• W2593623152 abstract "Abstract [Background] Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma, characterized by the overexpression of cyclin D1 derived from t(11;14)(q13;q32) and poor prognosis. Most MCLs show nodal presentation, but also accompany extranodal involvement, such as bone marrow, peripheral blood or gastrointestinal tract. As a result, many MCLs present with advanced stage disease. Since only a small portion of patients show limited-stage disease, minimal data exist on treatment of patients diagnosed with limited stage disease. Nevertheless, the treatment strategy of MCL is recommended according to the clinical stage of limited- (stage I or non-bulky II) vs. advanced-stage, as well as other types of lymphoma. [Patients and methods] We recently collected 633 patient data of MCL (Chihara, et al. Ann Oncol 2015). Information of clinical stage was available in 626 patients. The patient data were retrospectively analyzed the by the clinical stage at initial presentation. [Results] The clinical stage was I in 24 patients (4%), II in 33 (5%), III in 70 (11%), and IV in 499 (80%). Only one patient presented with bulky stage II. Detailed demographic information by the clinical stage are listed in Table. Age and sex were not significantly different by clinical stage. Limited stage patients were associated with better performance status (PS), less B symptoms, no extranodal involvement, and lower lactate dehydrogenase (LDH) level and white blood cell (WBC) count. Most patients in any stage were treated with cytotoxic chemotherapy, but more patients in limited stage received radiotherapy. The proportion of high-dose cytarabine (HDCA)-containing regimen over CHOP/CHOP-like was higher in advanced stage patients. Complete and overall response rates were 92% and 96% in stage I, 58% and 94% in stage II, 66% and 86% in stage III, and 52% and 82% in stage IV, respectively (P = 0.02). However, the higher response rate in limited stage patients did not translate into better prognosis. The median survival was 11.0 years in stage I, 13.4 years in stage II, 11.5 years in stage III, and 5.6 years in stage IV (Figure). The prognosis was not significantly different among patients with stage I, II, and III (P = 0.33). [Conclusion] Prognosis of limited-stage MCL was almost similar to that of stage III MCL. Although the present study includes several limitations including a retrospective nature and limited number of patients, prognosis of patients with limited-stage MCL was not satisfactory. The significance of radiotherapy, as well as the optimal choice of chemotherapy, for limited-stage MCL needs re-evaluation. Table Table. Figure Figure. Disclosures Suzuki: Chugai: Honoraria; Kyowa Hakko kirin: Honoraria; Bristol-Myers Squibb: Honoraria. Asano:Jannsen: Honoraria; Chugai: Honoraria. Kinoshita:Ono: Research Funding; Gilead: Research Funding; Zenyaku: Honoraria, Research Funding; Takeda: Research Funding; Chugai: Honoraria, Research Funding; Eisai: Honoraria, Research Funding; Solasia: Research Funding; Janssen: Honoraria; Kyowa Kirin: Honoraria. Suzumiya:Chugai: Honoraria, Research Funding; Astellas: Research Funding; Eisai: Honoraria, Research Funding; Takeda: Honoraria; Toyama Chemical: Research Funding; Kyowa Hakko kirin: Research Funding. Ogura:SymBio Pharmaceuticals: Consultancy, Honoraria; Celltrion, Inc.: Consultancy, Honoraria." @default.
• W2593623152 created "2017-03-16" @default.
• W2593623152 creator A5015509689 @default.
• W2593623152 creator A5025340212 @default.
• W2593623152 creator A5037147135 @default.
• W2593623152 creator A5046638834 @default.
• W2593623152 creator A5055368165 @default.
• W2593623152 creator A5067816264 @default.
• W2593623152 creator A5069130284 @default.
• W2593623152 creator A5078914737 @default.
• W2593623152 date "2016-12-02" @default.
• W2593623152 modified "2023-10-01" @default.
• W2593623152 title "Limited-Stage Mantle Cell Lymphoma" @default.
• W2593623152 doi "https://doi.org/10.1182/blood.v128.22.5330.5330" @default.
• W2593623152 hasPublicationYear "2016" @default.
• W2593623152 type Work @default.
• W2593623152 sameAs 2593623152 @default.
• W2593623152 citedByCount "1" @default.
• W2593623152 countsByYear W25936231522019 @default.
• W2593623152 crossrefType "journal-article" @default.
• W2593623152 hasAuthorship W2593623152A5015509689 @default.
• W2593623152 hasAuthorship W2593623152A5025340212 @default.
• W2593623152 hasAuthorship W2593623152A5037147135 @default.
• W2593623152 hasAuthorship W2593623152A5046638834 @default.
• W2593623152 hasAuthorship W2593623152A5055368165 @default.
• W2593623152 hasAuthorship W2593623152A5067816264 @default.
• W2593623152 hasAuthorship W2593623152A5069130284 @default.
• W2593623152 hasAuthorship W2593623152A5078914737 @default.
• W2593623152 hasConcept C126322002 @default.
• W2593623152 hasConcept C143998085 @default.
• W2593623152 hasConcept C146357865 @default.
• W2593623152 hasConcept C151730666 @default.
• W2593623152 hasConcept C2776581026 @default.
• W2593623152 hasConcept C2776694085 @default.
• W2593623152 hasConcept C2777525834 @default.
• W2593623152 hasConcept C2779338263 @default.
• W2593623152 hasConcept C2779714933 @default.
• W2593623152 hasConcept C2780007613 @default.
• W2593623152 hasConcept C71924100 @default.
• W2593623152 hasConcept C86803240 @default.
• W2593623152 hasConcept C90924648 @default.
• W2593623152 hasConceptScore W2593623152C126322002 @default.
• W2593623152 hasConceptScore W2593623152C143998085 @default.
• W2593623152 hasConceptScore W2593623152C146357865 @default.
• W2593623152 hasConceptScore W2593623152C151730666 @default.
• W2593623152 hasConceptScore W2593623152C2776581026 @default.
• W2593623152 hasConceptScore W2593623152C2776694085 @default.
• W2593623152 hasConceptScore W2593623152C2777525834 @default.
• W2593623152 hasConceptScore W2593623152C2779338263 @default.
• W2593623152 hasConceptScore W2593623152C2779714933 @default.
• W2593623152 hasConceptScore W2593623152C2780007613 @default.
• W2593623152 hasConceptScore W2593623152C71924100 @default.
• W2593623152 hasConceptScore W2593623152C86803240 @default.
• W2593623152 hasConceptScore W2593623152C90924648 @default.
• W2593623152 hasLocation W25936231521 @default.
• W2593623152 hasOpenAccess W2593623152 @default.
• W2593623152 hasPrimaryLocation W25936231521 @default.
• W2593623152 hasRelatedWork W2304731603 @default.
• W2593623152 hasRelatedWork W2519601971 @default.
• W2593623152 hasRelatedWork W2556510606 @default.
• W2593623152 hasRelatedWork W2557107624 @default.
• W2593623152 hasRelatedWork W2582243770 @default.
• W2593623152 hasRelatedWork W2588795721 @default.
• W2593623152 hasRelatedWork W2595988118 @default.
• W2593623152 hasRelatedWork W2795321683 @default.
• W2593623152 hasRelatedWork W2905419906 @default.
• W2593623152 hasRelatedWork W2913479341 @default.
• W2593623152 hasRelatedWork W2924618483 @default.
• W2593623152 hasRelatedWork W2948937712 @default.
• W2593623152 hasRelatedWork W2954522556 @default.
• W2593623152 hasRelatedWork W2973178253 @default.
• W2593623152 hasRelatedWork W2979847878 @default.
• W2593623152 hasRelatedWork W2979967851 @default.
• W2593623152 hasRelatedWork W2980076611 @default.
• W2593623152 hasRelatedWork W2984503273 @default.
• W2593623152 hasRelatedWork W2986592300 @default.
• W2593623152 hasRelatedWork W2991009694 @default.
• W2593623152 isParatext "false" @default.
• W2593623152 isRetracted "false" @default.
• W2593623152 magId "2593623152" @default.
• W2593623152 workType "article" @default.